跳至主要内容
临床试验/CTRI/2024/09/074281
CTRI/2024/09/074281尚未招募2 期

Efficacy and safety of pioglitazone in improving cognitive function among patients with impaired cognition as an add on therapy- a double blind randomized controlled study

未提供1 个研究点 分布在 1 个国家目标入组 330 人开始时间: 2024年10月7日最近更新:

试验速览

阶段
2 期
状态
尚未招募
入组人数
330
试验地点
1
主要终点
The primary outcome measures will be changes in MoCA Score and amyloid beta 42 40 ratio before and after the treatment.

研究概览

简要总结

This study is a randomized, double blind, parallel group, assessing the safety and efficacy of 15mg pioglitazone daily for 6 months in 330 patients with type 2 diabetes and having cognitive decline. It will be conducted in a single center in India. The primary outcome measures will be changes in MoCA Score and Amyloid beta 42 40 ratio at the time points: 2nd month, 4th month, 6th month and 12th month. The secondary outcome will be change in EEG-P300 wave, assessment of adverse drug reactions (ADRs), quality of life and medication adherence using the same time points as stated in primary end point

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant, Investigator and Outcome Assessor Blinded

入排标准

年龄范围
50.00 Year(s) 至 80.00 Year(s)(—)
性别
All

入选标准

  • Patients with cognitive impairment (MoCA scale below 26) Individuals willing to participate in the study Patients on standard therapy managing their neurological conditions.

排除标准

  • Patients on insulin medication Uncontrolled hypertension (SBP above150/90 mm/Hg) Patients with bladder cancer, kidney, liver and heart complications Osteoporosis patients or those at high risk of fractures • Contraindicated medication usage • The participant has a known history of hypersensitivity to pioglitazone • Has a history or current diagnosis of macular edema or macular degeneration.

结局指标

主要结局

The primary outcome measures will be changes in MoCA Score and amyloid beta 42 40 ratio before and after the treatment.

时间窗: Time points will be the 2nd month, 4th month, 6th month and at 12th month

次要结局

  • The secondary outcome will be change in EEG-P300 wave, assessment of adverse drug reactions (ADRs), quality of life and medication adherence after every 2 months(Time points will be the 2nd month, 4th month, 6th month and at 12th month)

研究者

发起方
未提供
责任方
Principal Investigator
主要研究者

Ian Osoro Nyakina

SRM Institute of Science and Technology, Kattankulathur

研究点 (1)

Loading locations...

相似试验